Elicio Therapeutics, Inc. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Elicio Therapeutics, Inc. (ELTX) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $1.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- Elicio Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was $5.00K, a 83.87% decline year-over-year.
- Elicio Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $31.00K.
- Elicio Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $79.00K.
- Elicio Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $48.00K, a 118.18% increase from fiscal 2024.
- Elicio Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was $22.00K.
- Elicio Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $0.00.
- Elicio Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.00K 10-Q · filed 2026-08-13 | ||||||
| 2026-03-31 | $5.00K 10-Q · filed 2026-05-11 | ||||||
| 2025-12-31 | $48.00K 10-K · filed 2026-03-12 | ||||||
| 2025-09-30 | $144.00K 10-Q · filed 2025-11-13 | ||||||
| 2025-06-30 | $105.00K 10-Q · filed 2026-08-13 | ||||||
| 2025-03-31 | $31.00K 10-Q · filed 2026-05-11 | ||||||
| 2024-12-31 | $22.00K 10-K · filed 2026-03-12 | ||||||
| 2024-09-30 | -$5.00K 10-Q · filed 2025-11-13 | ||||||
| 2024-06-30 | -$41.00K 10-Q · filed 2025-08-07 | ||||||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | ||||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 | ||||||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-13 | ||||||
| 2023-06-30 | -$2.00K 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | $79.00K 10-Q · filed 2023-05-10 | ||||||
| 2022-12-31 | $0.00 10-K · filed 2024-03-29 | $181.00K 10-K · filed 2023-03-17 | |||||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 | $396.00K 10-Q · filed 2022-11-14 | |||||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | $202.00K 10-Q · filed 2022-08-15 | |||||
| 2022-03-31 | -$87.00K 10-Q · filed 2023-05-10 | ||||||
| 2021-12-31 | $3.00K 10-K · filed 2023-03-17 | ||||||
| 2021-09-30 | -$11.00K 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | $5.00K 10-Q · filed 2022-08-15 | ||||||
| 2021-03-31 | -$3.00K 10-Q · filed 2022-05-16 | ||||||
| 2020-12-31 | -$444.00K 10-K · filed 2022-03-30 | ||||||
| 2020-09-30 | -$157.00K 10-Q · filed 2021-11-12 | ||||||
| 2020-06-30 | $47.00K 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $233.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |